The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Bayer (XTRA:BAYN) has quietly staged a strong rebound over the past month, with shares up around 14% and roughly 34% in the ...
Zacks.com on MSN
BAYRY's 2025 Revival: Will the Momentum Continue in 2026?
Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
MedPage Today on MSN
PD-1 inhibitor raises PFS in advanced acral melanoma
First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
The league clash looked to be heading towards a stalemate at Whitley Park before the young Magpies, targeting back-to-back ...
The 2024–25 season saw several American players lift trophies in 2025, and the foursome of Ricardo Pepi, Sergiño Dest, Malik ...
It was a busy weekend for a selection of U.S. players in Europe, with goals scored and moves secured. Welcome to the USMNT ...
Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value ...
As we celebrate the festive season, what better gift than a rerank of the best, most in-form teams across Europe's top five leagues?
A protocol of KDIGO-recommended strategies in high-risk patients significantly reduces moderate-to-severe acute kidney injury ...
MedPage Today on MSN
Targeted drug for advanced pancreatic cancer sparks early enthusiasm
The early results showed that 15 of 41 evaluable patients had objective responses and 32 had stable disease with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results